Specialty-Financed Licensing Deal Delivers Strong De-Risking: OSRH executed an $815 million definitive exclusive license agreement with BCME for global development, commercialization, and out-licensing of VXM01. The agreement’s specialty-financed structure – increasingly common among development-stage assets – is consistent with market trends and represents a de-risking milestone (e.g., OSRH is slated to receive at least $15 million cash within six months, even in a worst-case scenario). This important step, combined with impressive named global corporate partners at Woori IO (i.e., noninvasive blood glucose monitoring) bodes well. Shares experienced volatility in the wake of the announcement, creating a potential floor. If OSRH now grows 4PL, profitably integrates Woori IO, and successfully develops drug candidates, price upside is substantial.
